New paradigms in the diagnosis and management of endometriosis

Kavoussi SK, Shahryar K. Kavoussi, Lim CS, Courtney S. Lim, Skinner BD, Bethany Skinner, Bethany D Skinner, Dan I. Lebovic, Sawsan As‐Sanie, Sawsan As-Sanie
Current opinion in obstetrics & gynecology · 2016 · vol. 28(4) , pp. 267–276 · doi:10.1097/gco.0000000000000288 · PMID:27306924 · W2440868582
review OA: closed CC0 ⤵ 28 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review highlights advances in endometriosis diagnosis, noting the lack of validated noninvasive markers and the potential of fluorescence imaging, while reviewing current and novel hormone suppression therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE OF REVIEW: Endometriosis is a common gynecologic condition estimated to affect 10-15% of reproductive-aged women, 30% of women with subfertility, and 80% of women with chronic pelvic pain. Although mainstays of diagnosis and treatment are still commonly applied, there have been various advances in the modalities of diagnosis and management of this complex condition. This article provides an updated review of novel findings regarding the diagnosis and management of this challenging disease. RECENT FINDINGS: Despite an abundance of studies on noninvasive diagnostic markers for endometriosis, there is no single imaging study, biomarker or panel of biomarkers that has been validated for clinical diagnosis. New technologies, such as use of indocyanine green and fluorescence, which visualize neovascularization often associated with endometriosis may improve diagnostic detection of endometriosis at the time surgery, but have not been demonstrated to improve pain outcomes after surgery. Hormone suppression remains the mainstay therapy prior to and following surgery. Although most methods demonstrate similar efficacy in reducing endometriosis-associated pain, newer pharmacologic agents that may prove advantageous include oral gonadotropin receptor antagonists, selective progesterone receptor modulators, and angiogenesis inhibitors. SUMMARY: Although there have been some advances in the study of noninvasive imaging and biomarkers, more investigation into effective modalities are being conducted and are needed.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Endometriosis Infertility, Female Reproductive Health Reproductive Health Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Endometriosis Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Infertility, Female Laparoscopy Laparoscopy Magnetic Resonance Imaging Pelvic Pain Practice Guidelines as Topic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (29)

Source provenance

europepmc
last seen: 2026-07-30T06:25:42.655704+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:00.404924+00:00
License: CC0 · commercial use OK